

Role of Annexin A2 in Ovarian Cancer Metastasis

A Thesis Submitted for the Degree of Doctor of Philosophy by

Noor Alia Lokman



Robinson Institute, Research Centre for Reproductive Health,
Discipline of Obstetrics and Gynaecology,
School of Paediatrics and Reproductive Health, Faculty of Health Sciences,
The University of Adelaide, Australia

February 2014

Mak and Ayah, this is for you, I love you so much.

This thesis is dedicated to my loving parents, Norma Muhammad and Lokman Abdul Hamid.

Table of Contents

List of Figures	8
List of Supplementary Figures	10
List of Tables	11
List of Supplementary Tables	12
Summary	13
Declaration.....	15
Acknowledgements.....	16
Publications Arising During Ph D Candidature.....	17
Publications Contributing to This Thesis	18
Presentations at Scientific Meeting.....	19
Awards Arising Out of This Thesis.....	22
Abbreviations	23
Chapter 1: The Role of Annexin A2 in Tumourigenesis and Cancer Progression.....	25
1.1 Abstract.....	28
1.2 Introduction	29
1.3 The structure and function of annexin A2	29
1.4 Expression of annexin A2 in cancer.....	30
1.5 Role of annexin A2 and its binding proteins in cancer	31
1.6 Role of annexin A2 in the plasminogen activator system.....	32
1.7 Role of annexin A2 in cancer cell adhesion, invasion, and migration.....	33
1.8 Post translational modifications and proteolytic cleavage of annexin A2 in cancer cells	34
1.9 Annexin A2 and ovarian cancer	35
1.10 Annexin A2 as a potential therapeutic target in cancer	36
1.11 Conclusions and future directions	37
1.12 Acknowledgement.....	37

1.13	Statement of hypotheses, aims and research plan	44
1.13.1	Hypotheses.....	44
1.13.2	Aims.....	44
1.13.3	Research plan.....	45
	Chapter 2: Chick Chorioallantoic Membrane (CAM) Assay as an <i>In Vivo</i> Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion and Metastasis	46
2.1	Abstract.....	49
2.2	Introduction	50
2.3	Materials and methods.....	51
2.3.1	Cell culture.....	51
2.3.2	Cell motility and invasion assays	51
2.3.3	Chick chorioallantoic membrane assay (CAM Assay).....	51
2.3.4	Immunohistochemistry	52
2.3.5	Statistical analysis.....	52
2.4	Results.....	53
2.4.1	Human ovarian cancer cell motility and invasion in vitro.....	53
2.4.2	Human ovarian cancer cell invasion into the chick chorioallantoic membrane (CAM)	53
2.4.3	The effects of protein A neutralizing antibody on OV-90 cancer cell invasion into the CAM.....	54
2.5	Discussion	60
2.6	Conclusions	63
2.7	Acknowledgments.....	63
	Chapter 3: Annexin A2 is regulated by Ovarian Cancer-Peritoneal Cell Interactions and Promotes Metastasis.....	64
3.1	Abstract.....	69
3.2	Introduction.....	70

3.3	Materials and methods.....	72
3.3.1	Patient's tissue samples	72
3.3.2	Cell culture.....	72
3.3.3	Real-time PCR.....	73
3.3.4	Immunohistochemistry	73
3.3.5	Cytokeratin immunocytochemistry	73
3.3.6	Co-culture of ovarian cancer and peritoneal cells	74
3.3.7	1D-western immunoblotting	74
3.3.8	2D-western immunoblotting	74
3.3.9	Motility and invasion assays	75
3.3.10	Adhesion assay	75
3.3.11	Chick chorioallantoic membrane assay.....	75
3.3.12	Intraperitoneal SKOV-3 xenograft mouse model.....	76
3.3.13	Immunohistochemical assessment	76
3.3.14	Statistical analysis.....	77
3.4	Results.....	78
3.4.1	Expression of annexin A2 in human ovarian cancer tissues and peritoneal cells	78
3.4.2	Morphology of primary ovarian cancer cells derived from ascites.....	78
3.4.3	Annexin A2 expression in primary ovarian cancer cells	79
3.4.4	Expression of annexin A2 in human ovarian cancer and peritoneal cell lines	79
3.4.5	Annexin A2 is cleaved in ovarian cancer and peritoneal cells co-culture	79
3.4.6	Annexin A2 is cleaved by protease plasmin.....	80
3.4.7	Annexin A2 promotes ovarian cancer motility and invasion and aids peritoneal adhesion of ovarian cancer cells.....	80
3.4.8	Annexin A2 promotes ovarian cancer cell invasion in the chick chorioallantoic membrane model.....	81

3.4.9	Annexin A2 promotes primary ovarian cancer cell invasion in the CAM model..	81
3.4.10	Annexin A2 promotes ovarian cancer growth and metastasis	81
3.5	Discussion	96
3.6	Acknowledgements.....	98
	Chapter 4: Annexin A2 as a Diagnostic Marker for Serous Ovarian Cancer	107
4.1	Abstract.....	108
4.2	Introduction.....	109
4.3	Materials and methods.....	111
4.3.1	Urine, serum and plasma samples.....	111
4.3.2	Urine sample preparation for western blot and annexin A2 ELISA	111
4.3.3	1D-western immunoblotting	111
4.3.4	Annexin A2 ELISA and detection of CA125	112
4.3.5	Statistical analyses	112
4.4	Results.....	113
4.4.1	Level of annexin A2 in the urine of ovarian cancer patients	113
4.4.2	Blood annexin A2 levels are elevated in serous ovarian cancer patients compared with non-cancer controls	113
4.4.3	CA125 levels in serous ovarian cancer patients	113
4.4.4	Annexin A2 levels are weakly correlated with CA125 and able to distinguish serous ovarian cancer patients with normal CA125 levels from non-cancer controls	114
4.4.5	Annexin A2 and CA125 diagnostic performance in ovarian cancer patients compared with non-cancer controls using specified cut points	114
4.4.6	Annexin A2 and CA125 diagnostic performance in serous ovarian cancers compared with benign ovarian tumour using specified cutoff points	115
4.4.7	Logistic regression model to evaluate the efficacy of combining annexin A2 and CA125 measurements in ovarian cancer patients and non-cancer controls	115

4.4.8	Logistic regression model to evaluate the efficacy of combining annexin A2 and CA125 measurements in ovarian cancer patients versus patients with benign ovarian tumours	116
4.5	Discussion	128
4.6	Acknowledgements.....	130
	Chapter 5: Prognostic Significance of Annexin A2 and S100A10 in Serous Ovarian Cancer	133
5.1	Abstract.....	134
5.2	Introduction.....	135
5.3	Materials and methods.....	137
5.3.1	Patient's tissue microarray cohort.....	137
5.3.2	Immunohistochemistry	137
5.3.3	Immunohistochemical assessment	137
5.3.4	Statistical analyses	137
5.4	Results.....	139
5.4.1	Increased stromal annexin A2 and S100A10 expression in metastatic ovarian cancer tissues compared with matching primary ovarian tumours.....	139
5.4.2	High stromal annexin A2 expression in the cancer associated stroma predicts clinical outcome	139
5.4.3	S100A10 cytoplasmic positivity is associated with reduced survival.....	139
5.4.4	Stromal annexin A2 positivity and cytoplasmic S100A10 expression is an independent predictor of clinical outcome.....	140
5.5	Discussion	152
5.6	Acknowledgements.....	154
	Chapter 6: General Discussion and Conclusions.....	156
6.1	General discussion	157
6.1.1	Annexin A2 plays an important role in ovarian cancer invasion and metastasis	158

6.1.2	Role of annexin A2 in tumour microenvironment	159
6.1.3	Clinical significance of annexin A2 in serous ovarian cancer patients	161
6.1.4	Co-localization of annexin A2 and S100A10 proteins in ovarian cancer cells ..	162
6.2	Future directions	163
6.3	Conclusions	164
References	167
Appendix	185

List of Figures

Figure 1.1 Annexin A2 domain structure.....	38
Figure 1.2 2D-gel electrophoresis of proteins in co-cultured ovarian cancer and peritoneal cell....	39
Figure 1.3 Annexin A2 expression in human ovarian tumour tissues.....	40
Figure 1.4 Proposed mechanism of annexin A2 promoting cancer metastasis in the plasminogen activation system.	41
Figure 2.1 Motility and invasion of human ovarian cancer cell lines (OVCAR-3, SKOV-3 and OV-90) <i>in vitro</i>	55
Figure 2.2 Chick embryo development.	56
Figure 2.3 Invasion of ovarian cancer cells in the chick chorioallantoic membrane (CAM).	57
Figure 2.4 Chick chorioallantoic membrane (CAM) invasion by ovarian cancer cells in day 14 chick embryos.....	58
Figure 2.5 Effects of protein A neutralizing antibody on OV-90 cancer cell invasion into the chick chorioallantoic membrane (CAM).	59
Figure 3.1 Annexin A2 immunostaining in human ovarian tissues and omental tissues.	83
Figure 3.2 Morphology of primary ovarian cancer cell lines derived from patients ascites.....	85
Figure 3.3 Annexin A2 expression in primary ovarian cancer cells.....	86
Figure 3.4 Annexin A2 expression in ovarian cancer cell lines, peritoneal cell line and co-cultured ovarian cancer and peritoneal cells.	87
Figure 3.5 The effects of annexin A2 siRNA knockdown on ovarian cancer cell motility, invasion and adhesion <i>in vitro</i>	88
Figure 3.6 Annexin A2 promotes OV-90 cell motility and invasion <i>in vitro</i> and <i>in vivo</i>	90
Figure 3.7 Neutralizing annexin A2 antibody inhibits primary ovarian cancer cells invasion in the CAM model.....	92
Figure 3.8 Annexin A2 promotes growth and metastasis of SKOV-3 cells.....	94
Figure 3.9 Annexin A2 neutralizing antibodies increase apoptosis.	95
Figure 4.1 Annexin A2 expression in controls and ovarian cancer patient's urine.	118
Figure 4.2 Annexin A2 and CA125 levels in normal ovaries, benign ovarian tumours and serous ovarian cancers.	120
Figure 4.3 Correlation of annexin A2 and CA125 levels.	121
Figure 4.4 ROC curves from logistic regression analysis for annexin A2, CA125 and combined annexin A2 and CA125 measurements.	123
Figure 5.1 Annexin A2 and S100A10 immunostaining in stage III serous ovarian cancers	143

Figure 5.2 Annexin A2 and S100A10 immunostaining in primary ovarian tumour and matching metastasis tissues.	144
Figure 5.3 High stromal annexin A2 expression is associated with poor prognosis in stage III serous ovarian cancer patients.	146
Figure 5.4 S100A10 cytoplasmic expression is associated with reduced overall survival for stage III serous ovarian cancer patients.	148
Figure 6.1 The mechanism of annexin A2 in cancer progression	165
Figure 6.2 The effects of annexin A2 inhibitors on cancer cell invasion and metastasis	166

List of Supplementary Figures

Supplementary Figure 3.1 Ion-trap mass spectrometry LC-MS/MS analysis of annexin A2 spots from the 2D gel electrophoresis.....	100
Supplementary Figure 3.2 Annexin A2 expression after knockdown with annexin A2 siRNAs. ...	101
Supplementary Figure 3.3 IVIS imaging of mice.....	102

List of Tables

Table 1.1 Annexin A2 expression in cancer.....	42
Table 1.2 Summary of the effects of annexin A2 on cancer cells.	43
Table 2.1 Comparison of the advantages and limitations of the chick chorioallantoic membrane (CAM) and mouse model.....	62
Table 4.1 Comparison of annexin A2 and CA125 marker sensitivity, specificity, PPV and NPV for controls (normal ovaries and benign ovarian tumours) and serous ovarian cancers using specified cutoff points.	124
Table 4.2 Comparison of annexin A2 and CA125 markers sensitivity, specificity, PPV and NPV for benign ovarian tumours and serous ovarian cancers using specified cutoff points.....	125
Table 4.3 Comparison of annexin A2 and CA125 markers in controls (normal ovaries and benign ovarian tumours) and serous ovarian cancers using logistic regression and ROC curve analyses.	126
Table 4.4 Comparison of annexin A2 and CA125 markers in benign ovarian tumours and serous ovarian cancers using logistic regression and ROC curve analyses.....	127
Table 5.1 Correlation of annexin A2 and S100A10 immunostaining in the membrane and cytoplasm of cancer cells and cancer associated stroma in stage III primary serous ovarian cancer.	149
Table 5.2 Correlation of annexin A2 stromal intensity with age, tumour grade and residual disease in stage III primary serous ovarian cancer.	150
Table 5.3 Cox Regression analyses of stage III serous ovarian cancer patient cohort.....	151

List of Supplementary Tables

Supplementary Table 3.1 Annexin A2 epithelial and stromal immunostaining intensity in the normal ovaries, serous cystadenomas, serous borderline tumours and serous ovarian carcinomas (stage I-IV) tissues.....	103
Supplementary Table 3.2 Annexin A2 epithelial and stromal immunostaining intensity in the primary tumour and matching omental metastasis tissues.	104
Supplementary Table 3.3 Annexin A2 epithelial immunostaining intensity in the omental tissues.	105
Supplementary Table 3.4 Clinical characteristics of primary ovarian cancer cell lines derived from patients' ascites.	106
Supplementary Table 4.1 Clinicopathological characteristics of urine patient cohort.....	131
Supplementary Table 4.2 Clinicopathological characteristics of serum or plasma patient cohort.	132
Supplementary Table 5.1 Clinicopathological characteristics of stage III serous ovarian cancer patient tissue cohort.....	155

Summary

Ovarian cancer is the most lethal gynaecological cancer. We identified annexin A2 to be modulated in the co-culture of ovarian cancer and peritoneal cells *in vitro*. Annexin A2, a calcium phospholipid binding protein, has been characterized in many malignancies and mediates various cellular functions such as cell motility, invasion, proliferation, angiogenesis and cell adhesion. Annexin A2 heterotetramer consists of annexin A2 and S100A10 monomers on the cell surface and plays an important role in the plasminogen activator system that enhances cancer cell invasion and metastasis. The aim of this Ph D thesis was to investigate the role of annexin A2 in ovarian cancer metastasis using *in vitro* and *in vivo* ovarian cancer models.

Annexin A2 expression was characterized in serous ovarian cancer cell lines and human serous ovarian cancer tissues. Annexin A2 inhibitors were used to evaluate the effects of annexin A2 on ovarian cancer cell motility, invasion and adhesion to the peritoneal cells. Furthermore, annexin A2 neutralizing antibodies were used to examine the role of annexin A2 in tumour invasion and metastasis using a chick chorioallantoic membrane (CAM) assay and an intraperitoneal xenograft mouse model. We evaluated whether annexin A2 can be used as a diagnostic marker by measuring blood annexin A2 levels in serous ovarian cancer patients. Moreover, annexin A2 and its binding protein, S100A10 expression were assessed using immunohistochemistry to determine their relationship with clinical outcome in a cohort of stage III serous ovarian cancers.

We showed that annexin A2 immunostaining was significantly increased in cancer-associated stromal cells compared with non-malignant ovarian tissues. Annexin A2 siRNAs significantly inhibited ovarian cancer cell motility, invasion and adhesion to peritoneal cells. Moreover, annexin A2 neutralizing antibodies significantly inhibited OV-90 cell motility and invasion *in vitro* and in the *in vivo* CAM assay. Furthermore, we also demonstrated that annexin A2 neutralizing antibodies significantly inhibited the invasion of primary ovarian cancer cell lines in the CAM assay. The growth of SKOV-3/GFP Luc cells and peritoneal dissemination in nude mice was significantly inhibited by annexin A2 neutralizing antibodies. Our findings suggested that reduced tumour burden and metastatic spread was a result of reduced cell survival.

Blood annexin A2 levels were increased in early stage and advanced stage ovarian cancer patients compared with women without malignancy (normal ovaries and benign ovarian tumours). We showed an improved sensitivity for detecting early stage ovarian cancer by combining annexin A2 and CA125 at the 95% and 98% specificity level. Kaplan-Meier analyses of stage III serous ovarian cancers showed that high stromal annexin A2 expression was significantly associated with

reduced progression-free survival and overall survival. Moreover, we also showed high cytoplasmic S100A10 in the cancer cells to be associated with reduced overall survival. Both, high stromal annexin A2 and high cytoplasmic S100A10, were independent predictors of overall survival in a multivariate analysis which included positive residual disease.

In conclusion, our findings indicate that annexin A2 plays an important role in ovarian cancer tumourigenesis and metastasis is therefore a potential novel therapeutic target against ovarian cancer. We also demonstrated that annexin A2 has both diagnostic and prognostic significance and may be useful for serous ovarian cancer diagnosis and patient management.

Declaration

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for the award of any degree or diploma in any university; and that to the best of my knowledge and belief, this work does not contain any material previously published or written by any other person except where due reference is made in the text.

I give consent to the copy of my thesis to be deposited in the University Library to be made available for loan and photocopying, subject to embargoes, and the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the ADTP, and the library catalogue, subject to embargoes.

.....
Noor Alia Lokman

February 2014

Acknowledgements

I am grateful to a lot of people for their help and support throughout my Ph D experience. First of all, I would like to thank my supervisor, Dr Carmela Ricciardelli that has given me the best supervision over the last four years. Thank you for being patient, supportive, helping me out with my data analysis and a great mentor to me. I would like to thank my co-supervisor, Prof Martin Oehler for your supervision, guidance, ideas and discussion throughout my Ph D. Thank you Carmela and Martin for evaluating my manuscripts and being committed to my research project.

I would like to thank previous and present members of Reproductive Cancer group that assist me in my Ph D studies, Dr Miranda Ween, Dr Carmen Pyragius, Wendy Bonner, Dr Alison Elder and Dr Izza Tan for their friendship, technical assistance in the lab and manuscript evaluations.

I would like to thank A/Prof Peter Hoffmann and Karina Martin from Adelaide Proteomics Center for your assistance throughout my Ph D and also Prof Ray Rodgers, Dr Katja Hummitzsch and Nick Hatzirodos for their help throughout my PhD.

Previous and present Ph D students for their friendship and assistance throughout my studies: Nok, Lisa, Adrian, Jacky, Siew, Macarena, Zahied, Siti Mariam, Jess, Dulama, David, Vincent and Sally. Thank you all.

I am fortunate to receive scholarships from Adelaide Graduate Fee Scholarship, Florey Foundation, Faculty of Health Sciences and Robinson Institute for supporting my Ph D journey and opportunity to present my research in conferences. Thank you also to the staff of Discipline of Obstetrics and Gynaecology for excellent resources throughout my studies.

I'm also grateful to the patients at Royal Adelaide Hospital and Burnside Hospital that have given consent for their samples to be used in this study.

Thank you to my friends Ayuni, Suhana, Afifah and Solehah for your friendship and support.

To my best friend, Nur Hezrin Shahrin, for her continuous support in good and hard times and being a good listener in our coffee catch-up sessions in these past few years, all the best with your baby boy, Adyan Hamzah.

Finally, to my loving parents, Norma Muhammad and Lokman Abdul Hamid, for everything that they have done for me and made me who I am today. There's no way that I can thank you enough for your endless love, support and encouragement. Mak and ayah, I've been blessed to have both of you in my life, I love you so much. To my one and only sister, Dr Noor Dayana for her love and strong character, I'm so proud of you. To my brothers, Adi Ikmal, Dani Aizat and Dhiya Aiman, who always had been there for me. And to my family, Cik Yah, Cik Nin, Azwa and everyone for their love and support.

Publications Arising During Ph D Candidature

1. Ricciardelli C, Ween MP, **Lokman NA**, Tan IA, Pyragius CE and Oehler MK, Chemotherapy-induced hyaluronan production: A novel chemoresistance mechanism in ovarian cancer. *BioMed Central Cancer*, 2013, 13:476. (Impact factor: 3.33)
2. **Lokman NA**, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. *Oncotarget*, 2013, 4(8):1129-1211. (Impact factor: 6.636)
3. **Lokman NA**, Elder ASF, Ricciardelli C and Oehler MK, Chick chorioallantoic membrane (CAM) assay as an *in vivo* model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. *Int.J.Mol.Sci.*, 2012,13, 9959-9970. (Impact factor: 2.464)
4. **Lokman NA**, Ween MP, Oehler MK and Ricciardelli C, The role of annexin A2 in tumourigenesis and cancer progression. *Cancer Microenvironment*, 2011, 4, 199-208.
5. Ween MP, **Lokman NA**, Hoffmann P, Rodgers RJ, Ricciardelli C and Oehler MK, Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells, *Int.J. Cancer*, 2011,128, 1570-1584. (Impact factor: 6.198)

Publications Contributing to This Thesis

1. **Lokman NA**, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. *Oncotarget*, 2013, 4(8):1129-1211. (Impact factor: 6.636)
2. **Lokman NA**, Elder ASF, Ricciardelli C and Oehler MK, Chick chorioallantoic membrane (CAM) assay as an *in vivo* model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. *Int.J.Mol.Sci.*, 2012,13, 9959-9970. (Impact factor: 2.464)
3. **Lokman NA**, Ween MP, Oehler MK and Ricciardelli C, The role of annexin A2 in tumourigenesis and cancer progression. *Cancer Microenvironment*, 2011, 4, 199-208.

Presentations at Scientific Meeting

2013

Lokman NA, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis, Robinson Institute Research Symposium, 4th November 2013, National Wine Centre, Adelaide, South Australia, Australia. **(poster)**

Lokman NA, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis, Matrix Biology Society of Australia and New Zealand (MBSANZ), 20-23rd October 2013, McCracken Country Club, South Australia, Australia. **(oral and poster)**

Lokman NA, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis, Postgraduate Research Expo, Faculty of Health Science, University of Adelaide, 29th August 2013, National Wine Centre, Adelaide, South Australia, Australia. **(poster)**

Lokman NA, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis, The Centre for Personalised Cancer Medicine Symposium 'Driving personalised cancer medicine through next generation sequencing', 25th July 2013, National Wine Centre, Adelaide, South Australia, Australia. **(poster)**

2012

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour in ovarian cancer metastasis, Robinson Institute Research Symposium, 12th December 2012, National Wine Centre, Adelaide, South Australia, Australia. **(poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour in ovarian cancer metastasis, Cold Spring Harbor Asia/International Cancer Microenvironment

Society Joint Conference on Tumour Microenvironment, 13th to 17th November 2012, Suzhou Dushu Lake Conference Center, Suzhou, China. **(poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour in ovarian cancer metastasis, Frontiers in Cancer Science 2012, 5th to 8th November 2012, National University of Singapore, Singapore. **(poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour in ovarian cancer metastasis, Matrix Biology Society of Australia and New Zealand (MBSANZ) 2012, 5th to 8th September 2012, Mantra Legends, Gold Coast, Queensland, Australia. **(oral and poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour in ovarian cancer metastasis, 14th International Biennial Congress of the Metastasis Research Society, 2nd to 5th September 2012, Brisbane Convention Centre, Brisbane, Queensland, Australia. **(poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Annexin A2 released during ovarian cancer-peritoneal cell interaction promotes a pro-metastatic cancer cell behaviour. Postgraduate Research Expo, Faculty of Health Science, University of Adelaide, 31st August 2012, The National Wine Centre, Adelaide, South Australia, Australia. **(poster)**

2011

Lokman NA, Ween MP, Hoffmann P, Oehler MK. and Ricciardelli C, Role of Annexin A2 in ovarian cancer metastasis. Australian Society for Medical Research (ASMR), SA Scientific Meeting, Adelaide Convention Center, 7th June 2011, South Australian Division **(poster)**

2010

Lokman NA, Ween MP, Hoffmann P, Oehler MK. and Ricciardelli C, Role of Annexin A2 in ovarian cancer metastasis. Matrix Biology Society of Australia and New Zealand (MBSANZ) combined

meeting with the 5th Australian Health & Medical Research Congress 2010, 14th-18th November 2010, Melbourne Convention and Exhibition Centre, Victoria, Australia. **(oral and poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK and Ricciardelli C, Role of Annexin A2 in ovarian cancer metastasis, Postgraduate Research Expo, Faculty of Health Science, University of Adelaide, 1st September 2010, The National Wine Centre, Adelaide, South Australia, Australia. **(poster)**

Lokman NA, Ween MP, Hoffmann P, Oehler MK. and Ricciardelli C, Role of Annexin A2 in ovarian cancer metastasis. Australian Society for Medical Research (ASMR), SA Scientific Meeting, Adelaide Entertainment Centre, 9th June 2010, South Australian Division. **(oral)**

Awards Arising Out of This Thesis

1. High Commended - Student Poster Award, 2013 Robinson Institute Research Symposium, 4th November 2013, National Wine Centre, Adelaide, South Australia, Australia.
2. Vice-Chancellor's Prize for Best Poster, Faculty of Health Sciences Postgraduate Research Conference, 29th August 2013, National Wine Centre, Adelaide, South Australia, Australia.
3. Best Student Poster Award, 2012 Robinson Institute Research Symposium, 12th December 2012, National Wine Centre, Adelaide, South Australia, Australia.
4. Best Student Poster Award 2012, Matrix Biology Society of Australia and New Zealand (MBSANZ), 5th to 8th September 2012, Mantra Legends, Gold Coast, Queensland, Australia.

Abbreviations

E-ACA	6-Aminocaproic Acid
Ab	Antibody
ABC	ATP binding cassette
ANXA2	Annexin A2
CA125	Cancer Antigen 125
CAM	Chick Chorioallantoic Membrane
CD44	Cluster of Differentiation 44
CM	Conditioned Media
CMI	Cancer Cells and Matrigel Implant
DAB	Diaminobenzidine Tetrahydrochloride
ECT	Ectoderm
ECL	Enhanced chemiluminescence
ECM	Extracellular Matrix
EDTA	Ethylenediaminetetraacetic Acid
EMT	Epithelium-Mesenchymal Transition
END	Endoderm
ELISA	Enzyme Linked Immunosorbent Assay
ERK	Extracellular Signal Regulated Kinase
FBS	Fetal Bovine Serum
FIGO	International Federation of Gynaecologist and Obstetricians
GFP	Green Fluorescent Protein
GM6001	Galardin
H ₂ O ₂	Hydrogen Peroxide
HE4	Human Epididymis Protein 4
HCC	Hepatocellular Carcinoma
HCl	Hydrochloric Acid
Ig	Immunoglobulin
MAPK	Mitogen Activated Protein Kinase
MES	Mesoderm
MMPs	Matrix Metalloproteinases

N-terminal domain	Amino Terminus Domain
NPV	Negative Predictive Values
pI	Isoelectric Point
P11	Protein P11
PBS	Phosphate Buffered Saline
PBS-T	Phosphate Buffered Saline with Tween-20
PPV	Positive Predictive Values
RMI	Risk Malignancy Index
ROC	Receiver Operating Curve
ROMA	Risk of Ovarian Malignancy Algorithm
RR	Relative Risk
RT-PCR	Real-time Polymerase Chain Reaction
u-PA	Urokinase-Type Plasminogen Activator
SDS	Sodium Dodecyl Sulphate
siRNAs	Small Interfering RNAs
SKOV-3/GFP Luc	SKOV-3 cells labeled with GFP and Luciferase
t-PA	Tissue-Type Plasminogen Activator
TGFβ1p	Transforming Growth Factor Inducible Protein
Tris	Tris(hydroxymethyl)-aminomethane
TMA	Tissue Microarray
LC-MS/MS	Liquid Chromatography-Mass Spectrometry